Compare · FMS vs NIVF
FMS vs NIVF
Side-by-side comparison of Fresenius Medical Care AG (FMS) and NewGenIvf Group Limited (NIVF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and NIVF operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $13.13B, about 3732.8x NIVF ($3.5M).
- Both names hit the wire about 7 times in the past 4 weeks.
- FMS has more recent analyst coverage (23 ratings vs 0 for NIVF).
- Company
- Fresenius Medical Care AG
- NewGenIvf Group Limited
- Price
- $23.50-0.04%
- $0.55+8.51%
- Market cap
- $13.13B
- $3.5M
- 1M return
- -5.62%
- -
- 1Y return
- -7.83%
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 7
- Recent ratings
- 23
- 0
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest FMS
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery
- Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda
- Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by BNP Paribas Exane with a new price target
Latest NIVF
- SEC Form F-1 filed by NewGenIvf Group Limited
- SEC Form 3 filed by new insider Lee Sze Mun
- SEC Form 6-K filed by NewGenIvf Group Limited
- SEC Form 4 filed by Chairman & CEO Siu Wing Fung Alfred
- SEC Form 4 filed by Chief Marketing Officer Fong Hei Yue Tina
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGenIVF Completes Exchange of Convertible Notes with Institutional Investor
- SEC Form 6-K filed by NewGenIvf Group Limited
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen Provides Update on K25.ai Investment and Strengthened Financial Position